No Cell Therapy-Related Updates in October’s CHMP Agenda
On Monday, October 10, the CHMP agenda for October was released. As previously anticipated by the Celltelligence team, no cell therapy-related updates were observed. Recall that Breyanzi’s (BMS’s CD19 CAR-T) indication extension to 2L LBCL transplant-intended (TI) patients could potentially be included in November’s CHMP agenda (see previous insight).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.